In biology, knockdown refers to a laboratory technique that reduces the activity of a specific gene without permanently altering the organism’s DNA. Rather than deleting or disabling a gene entirely, knockdown lowers the amount of protein a gene produces, typically by 50% or more. This lets researchers study what happens when a gene is dialed down, revealing its role in normal cell function, disease, or development.
How Knockdown Differs From Knockout
The terms sound similar, but they describe fundamentally different approaches. A gene knockdown reduces gene expression at the RNA level, meaning the gene’s DNA sequence stays intact. The effect is temporary. Once the knockdown agent is used up or diluted through cell division, expression gradually returns to normal. A gene knockout, by contrast, permanently removes or disables the gene at the DNA level, eliminating its expression entirely.
This distinction matters in practice. Because knockdown is reversible, it’s useful for studying genes that cells need to survive. Permanently deleting such a gene would kill the cell before you could learn anything. Knockdown lets you partially suppress the gene and observe the consequences. The tradeoff is that some residual gene activity always remains, which can complicate results.
The RNAi Pathway
The most widely used knockdown method exploits a natural defense system called RNA interference, or RNAi. Cells already use this pathway to silence invading genetic material from viruses. Scientists hijack it by introducing small synthetic RNA molecules that trick the cell into destroying a specific messenger RNA (mRNA) before it can be translated into protein.
The process works in two steps. First, an enzyme called Dicer chops double-stranded RNA into short fragments roughly 20 to 25 nucleotides long, known as small interfering RNAs (siRNAs). Second, these fragments load into a protein complex called RISC. The RISC unwinds the siRNA into a single strand, which then hunts for a matching mRNA sequence. When it finds a perfect match, the RISC complex cuts the mRNA apart, preventing the cell from using it to make protein. If the match is imperfect, the mRNA isn’t destroyed but is blocked from being translated, still reducing protein output.
Researchers can trigger this pathway experimentally by introducing synthetic siRNAs directly into cells or by using short hairpin RNAs (shRNAs), which are DNA constructs that the cell processes into siRNAs on its own.
Other Knockdown Technologies
Antisense Oligonucleotides
Antisense oligonucleotides (ASOs) are short, synthetic stretches of modified DNA or RNA designed to bind a specific mRNA target. Once bound, the resulting hybrid recruits a cellular enzyme that chops the mRNA, reducing protein production. Some ASOs work differently: instead of triggering degradation, they physically block the cell’s protein-making machinery from reading the mRNA, or they alter how the mRNA is spliced together, changing which version of a protein the cell produces.
CRISPRi
A newer approach called CRISPRi (CRISPR interference) borrows from the gene-editing toolkit but skips the cutting. It uses a deactivated version of the Cas9 protein that can still find and bind to a specific DNA location but cannot cut the strand. When this complex parks itself on a gene’s promoter region (the stretch of DNA that initiates the gene’s transcription), it physically blocks the cell’s transcription machinery from reading the gene. The result is reduced mRNA production without any change to the DNA sequence. CRISPRi and RNAi both silence genes, but they act at different stages: CRISPRi prevents the mRNA from being made in the first place, while RNAi destroys mRNA after it’s already been produced.
Morpholinos
In developmental biology, especially in zebrafish research, morpholino oligonucleotides are the go-to knockdown tool. These synthetic molecules bind to mRNA and either block the ribosome from assembling (preventing translation) or interfere with how pre-mRNA is spliced. They’re injected directly into embryos at the one- to eight-cell stage, and tiny bridges between the early embryonic cells allow them to spread throughout the developing organism. Translational-blocking morpholinos can suppress both maternal and newly made transcripts, uncovering gene functions that wouldn’t show up in standard genetic screens.
Transient vs. Stable Knockdown
Not all knockdown experiments last the same amount of time. Transient knockdown, the more common approach, involves delivering siRNAs or similar molecules directly into cells. The effect typically lasts several days before the knockdown agent is lost through cell division or degradation. This is useful for quick experiments testing what a gene does in the short term.
For longer studies, researchers create stable knockdown cell lines. This usually involves using a viral delivery system, often a lentivirus, to integrate an shRNA-producing sequence into the cell’s genome. The cell then continuously generates its own knockdown molecules, sustaining gene suppression indefinitely as the cells divide. Stable knockdown is essential for experiments that run weeks or months, like tracking tumor growth or studying chronic disease models.
Measuring Knockdown Efficiency
A knockdown experiment is only as good as its validation. Researchers need to confirm that the target gene’s expression actually dropped and by how much. The two standard methods measure different levels of the process.
At the mRNA level, a technique called RT-qPCR quantifies how much messenger RNA remains after knockdown. This gives a precise percentage of reduction. At the protein level, Western blotting visualizes whether less protein is being produced, which is the ultimate proof that the knockdown worked. Western blotting is considered the gold standard, though it depends on having a reliable antibody for the target protein, which isn’t always available. A knockdown that reduces mRNA expression by 50% or more is generally classified as effective, though many well-optimized experiments achieve 70% to 90% reduction.
Off-Target Effects
One of the biggest challenges with knockdown is specificity. siRNAs and other knockdown agents can sometimes silence genes they weren’t designed to target, particularly if a short stretch of their sequence happens to match another mRNA in the cell. These off-target effects can produce misleading results, making it look like a gene has a function it doesn’t actually have, or masking the true effect of silencing the intended target.
To guard against this, researchers typically use multiple independent siRNAs targeting different regions of the same gene. If two or three different siRNAs all produce the same cellular effect, it’s far more likely the result is genuine rather than an artifact of off-target silencing. Rescue experiments, where the suppressed gene is reintroduced in a form the siRNA can’t recognize, provide additional confirmation.
Knockdown in Medicine
Gene knockdown has moved beyond the research lab and into the clinic. Four siRNA-based drugs have received FDA approval, each one silencing a specific gene to treat disease. Patisiran, approved in 2018, targets a liver-produced protein that misfolds and damages nerves and organs in hereditary transthyretin amyloidosis. Givosiran (2019) treats acute hepatic porphyria by silencing a gene involved in toxic buildup of heme precursors. Lumasiran (2020) reduces oxalate production in people with primary hyperoxaluria, a condition that causes recurrent kidney stones and kidney damage. Inclisiran (2021) lowers cholesterol by knocking down the gene for PCSK9, a protein that prevents the liver from clearing LDL cholesterol from the blood.
These drugs work on the same principle as laboratory knockdown: a synthetic siRNA enters liver cells, engages the RISC complex, and destroys specific mRNA transcripts. The difference is in the engineering. Each drug is chemically modified for stability and packaged to reach its target tissue after injection. Their success has validated knockdown as not just a research tool but a viable therapeutic strategy, with dozens more siRNA and related drugs now in clinical trials.